Increased turnover - closing in on positive result

.

Financial highlights Q1 2025

• Net Sales amounted to 22.0 MSEK (21.2), an increase of 4 percent over the same quarter in 2024.
• Operating Result amounted to -1.6 MSEK (-5.0).
• Net Result after financial items amounted to -1.9 MSEK (-5.1).
• EBITDA for the first quarter is positive at 0.8 MSEK   (-1.1).
• Earnings per share were -0.02 SEK (-0.07).
• Cash Balance amounted to 2.8 MSEK (2.8).
• Average Daily Treatment Revenue (ADTR)* was 268 TSEK (241) in the quarter

Business highlights during the period

• Dignitana signed a Distribution Agreement for Chronos Trade Medical to be the exclusive provider of DigniCap in Romania.
• Dignitana received a Notice of Allowance from the Korean Intellectual Property Office for a patent titled "Scalp Cooling Apparatus, Method and System.
• Dignitana joined a panel of MedTech leaders to discuss innovation at the Texas BioLife Summit. 

Business highlights after the period

• In April Dignitana exhibited at the Oncology Nursing Society Congress in Denver, Colorado.

Significant events during the period

• Dignitana announced that the Board of Directors unanimously recommended the shareholders accept  the public takeover offer made by Paxman.

Significant events after the period

• Paxman completed the public offer to Dignitana shareholders and extended the acceptance period.
• Dignitana announced an Extraordinary General Meeting is scheduled for 5 June 2025. The EGM is convened at the request of the shareholder Paxman AB (publ) holding more than ten 10 percent of the number of outstanding shares and votes in the Company as of the date of the notice. The Shareholder has requested that the EGM be held to resolve on the dismissal of the Company's current Board members and to resolve on the number of Board members, election of new Board members and election of a new Chairman of the Board.
• Dignitana announced the Annual General Meeting is scheduled for 26 June 2025. The Notice, which was published 22 May 2025, details numerous proposals for the AGM made by shareholder Paxman AB

Key Figures

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

.